Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
182103
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
345111
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
||
|
WHO-ATC |
R03DX09
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
||
|
WHO-ATC |
L04AC06
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
NUCALA (AUTHORIZED: ASTHMA)
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
676218
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/13/1116
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
||
|
WHO-VATC |
QL04AC06
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
||
|
NDF-RT |
N0000191872
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
56603701
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
90Z2UF0E52
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
m11905
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
C434107
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
1720597
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | RxNorm | ||
|
90Z2UF0E52
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108429
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
5061
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
100000090763
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
7876
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
DB06612
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
C157376
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
196078-29-2
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
Mepolizumab
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
SUB21650
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
MEPOLIZUMAB
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
KK-20
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | |||
|
N0000191871
Created by
admin on Mon Mar 31 20:55:23 GMT 2025 , Edited by admin on Mon Mar 31 20:55:23 GMT 2025
|
PRIMARY | Interleukin-5 Antagonists [MoA] |
ACTIVE MOIETY
